Borer Denton & Associates’s Quest Diagnostics DGX Stock Holding History

Borer Denton & Associates’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.34M	Sell	6,812 -100	-1%	-$19.4K	0.48%	36
2025 Q4	$1.2M	Hold	6,912	–	–	0.4%	37
2025 Q3	$1.32M	Buy	6,912 +500	+8%	+$88.7K	0.43%	37
2025 Q2	$1.15M	Hold	6,412	–	–	0.4%	39
2025 Q1	$1.08M	Sell	6,412 -450	-7%	-$73.9K	0.38%	38
2024 Q4	$1.04M	Buy	6,862 +287	+4%	+$44.6K	0.36%	38
2024 Q3	$1.02M	Hold	6,575	–	–	0.35%	37
2024 Q2	$900K	Sell	6,575 -300	-4%	-$41.1K	0.33%	37
2024 Q1	$915K	Hold	6,875	–	–	0.32%	37
2023 Q4	$948K	Sell	6,875 -350	-5%	-$46K	0.36%	37
2023 Q3	$880K	Sell	7,225 -1,385	-16%	-$185K	0.36%	37
2023 Q2	$1.21M	Hold	8,610	–	–	0.48%	34
2023 Q1	$1.22M	Sell	8,610 -300	-3%	-$42.9K	0.51%	34
2022 Q4	$1.39M	Hold	8,910	–	–	0.62%	33
2022 Q3	$1.09M	Sell	8,910 -450	-5%	-$59.3K	0.54%	33
2022 Q2	$1.24M	Sell	9,360 -750	-7%	-$102K	0.6%	31
2022 Q1	$1.38M	Buy	+10,110	New	+$1.41M	0.58%	33

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Borer Denton & Associates's DGX Position: Q1 2026 in Review

Borer Denton & Associates reduced its Quest Diagnostics (DGX) stake by 1.4% in Q1 2026, selling an estimated $19.4K and leaving 6,812 shares worth $1.34M. The position accounts for 0.48% of the portfolio, ranked #36.

Borer Denton & Associates first reported a position in DGX in Q1 2022 and has held it in 17 quarters since. The position peaked at $1.39M in Q4 2022. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Borer Denton & Associates held 6,812 shares of Quest Diagnostics worth $1.34M as of Q1 2026.
Borer Denton & Associates sold 100 Quest Diagnostics shares in Q1 2026, an estimated $19.4K.
Quest Diagnostics made up 0.48% of Borer Denton & Associates's portfolio in Q1 2026, its #36 holding.
Borer Denton & Associates first reported a position in Quest Diagnostics in Q1 2022 and has held it in 17 quarters since.
Borer Denton & Associates's Quest Diagnostics position peaked at $1.39M in Q4 2022.
1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Borer Denton & Associates's 13F filing for Q1 2026, filed 12 May 2026.